Aspen Aerogels, Inc. $ASPN Shares Bought by Trexquant Investment LP

Key Points

• Trexquant Investment LP boosted its stake in Aspen Aerogels, Inc. by 114.7%, acquiring an additional 459,582 shares, bringing its total holdings to approximately 860,246 shares worth $5.5 million.
• Aspen Aerogels recently reported that its operational revenue declined by 33.8% year-over-year, with earnings per share at ($0.04), surpassing analyst forecasts.
• Research analysts have mixed views on Aspen Aerogels, with ratings ranging from Strong Buy to Sell, and an average price target of $19.50.

Trexquant Investment LP boosted its holdings in Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 114.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 860,246 shares of the construction company's stock after buying an additional 459,582 shares during the quarter. Trexquant Investment LP owned approximately 1.05% of Aspen Aerogels worth $5,497,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ASPN. Envestnet Asset Management Inc. boosted its stake in Aspen Aerogels by 118.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 47,262 shares of the construction company's stock valued at $561,000 after acquiring an additional 25,620 shares in the last quarter. Barclays PLC boosted its stake in shares of Aspen Aerogels by 16.8% during the fourth quarter. Barclays PLC now owns 107,764 shares of the construction company's stock worth $1,280,000 after buying an additional 15,462 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Aspen Aerogels by 25.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,018,631 shares of the construction company's stock worth $23,983,000 after buying an additional 409,862 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Aspen Aerogels by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 35,782 shares of the construction company's stock worth $425,000 after buying an additional 2,118 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Aspen Aerogels by 38.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 42,451 shares of the construction company's stock worth $505,000 after buying an additional 11,688 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

ASPN has been the subject of several recent research reports. Barclays downgraded shares of Aspen Aerogels from an "equal weight" rating to an "underweight" rating and increased their target price for the stock from $7.00 to $16.00 in a research note on Monday, August 11th. Canaccord Genuity Group reduced their price objective on shares of Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $19.50.

Aspen Aerogels Price Performance

Shares of ASPN traded up $0.27 during mid-day trading on Friday, reaching $6.62. 1,844,959 shares of the company's stock were exchanged, compared to its average volume of 1,705,162. The company has a quick ratio of 3.31, a current ratio of 3.98 and a debt-to-equity ratio of 0.34. The company has a 50-day simple moving average of $7.08 and a two-hundred day simple moving average of $6.52. Aspen Aerogels, Inc. has a 52-week low of $4.16 and a 52-week high of $30.24. The company has a market cap of $544.81 million, a price-to-earnings ratio of -1.74 and a beta of 2.65.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The construction company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The business had revenue of $78.02 million during the quarter, compared to analysts' expectations of $72.53 million. During the same period last year, the company posted $0.21 EPS. The company's revenue was down 33.8% on a year-over-year basis. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS. On average, sell-side analysts predict that Aspen Aerogels, Inc. will post 0.17 EPS for the current fiscal year.

Insider Buying and Selling at Aspen Aerogels

In other news, CAO Santhosh P. Daniel sold 4,410 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.31, for a total transaction of $32,237.10. Following the completion of the transaction, the chief accounting officer directly owned 19,879 shares of the company's stock, valued at $145,315.49. This trade represents a 18.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by company insiders.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.